Amgen is a shareholder of Vigil Neuroscience, which is developing microglia-based treatments for neurodegenerative diseases.
Vigil Neuroscience, a US-based neurodegenerative disease drug developer backed by pharmaceutical firm Amgen, launched yesterday with $50m in series A funding.
Venture capital firms Atlas Venture and Northpond Ventures co-led the round, which included fellow VC firm Hatteras Venture Partners and Alexandria Venture Investments, the VC arm of real estate investment trust Alexandria Real Estate Equities.
Founded earlier this year, Vigil is working on precision medical treatments that will combat neurodegenerative diseases by restoring the vigilance of microglia, the collective…
